Published in Ann Neurol on July 10, 2014
Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology (2015) 0.93
The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden. J Alzheimers Dis (2015) 0.87
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics (2016) 0.84
Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. Psychopharmacology (Berl) (2015) 0.82
Antibody-associated epilepsies: Clinical features, evidence for immunotherapies and future research questions. Seizure (2016) 0.81
Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis. Proc Natl Acad Sci U S A (2015) 0.81
Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. J Neurol (2014) 0.78
Autoimmune encephalitis in psychiatric institutions: current perspectives. Neuropsychiatr Dis Treat (2016) 0.78
Characteristic Cytokine and Chemokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Aetiology. PLoS One (2016) 0.76
Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system. J Neuroinflammation (2016) 0.76
Multicentric Castleman's disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report. BMC Neurol (2015) 0.75
Emergence of new-onset psychotic disorder following recovery from LGI1 antibody-associated limbic encephalitis. BMJ Case Rep (2017) 0.75
Neuronal antibodies in pediatric epilepsy: Clinical features and long-term outcomes of a historical cohort not treated with immunotherapy. Epilepsia (2016) 0.75
Autoimmune encephalitis following haematopoietic stem cell transplant: a new clinical entity or a previously unrecognised one? Transl Pediatr (2015) 0.75
HLA DRB1*03 as a possible common etiology of schizophrenia, Graves' disease, and type 2 diabetes. Ann Gen Psychiatry (2017) 0.75
Pediatric Autoimmune Disorders Associated with Streptococcal Infections and Tourette's Syndrome in Preclinical Studies. Front Neurosci (2016) 0.75
Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System. Front Immunol (2017) 0.75
Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and Hypotheses. Front Psychiatry (2017) 0.75
Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens. Neurol Sci (2017) 0.75
A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter. Neurol Sci (2017) 0.75
Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results. J Neurol (2017) 0.75
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol (2008) 21.53
Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol (2007) 16.81
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol (2013) 11.47
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol (2011) 10.82
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol (2009) 9.25
Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol (2010) 7.97
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain (2004) 7.38
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol (2011) 6.77
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology (2014) 6.73
Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol (2009) 5.75
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology (2004) 4.74
Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol (2014) 4.69
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol (2009) 4.49
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2008) 4.31
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol (2013) 4.18
The etiologic classification of epilepsy. Epilepsia (2011) 3.88
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67
The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis (2012) 3.63
Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science (2006) 3.52
Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain (2008) 3.51
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 3.40
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature (2005) 3.25
Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain (2013) 3.22
Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol (2012) 3.20
Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol (2012) 3.12
Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol (2001) 3.06
Rapidly progressive dementia. Ann Neurol (2008) 3.00
Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain (2012) 2.99
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol (2011) 2.98
N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol (2012) 2.91
Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology (2013) 2.82
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80
Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol (2007) 2.66
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol (2010) 2.54
Serum antibodies in epilepsy and seizure-associated disorders. Neurology (2005) 2.53
Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology (2013) 2.52
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol (2014) 2.36
Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry (2013) 2.33
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol (2009) 2.25
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry (2012) 2.15
Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology (2008) 2.13
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. JAMA Neurol (2013) 2.12
Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10
Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology (2008) 2.06
N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol (2009) 2.03
Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry (2013) 2.02
Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00
Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology (2011) 1.93
NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology (2010) 1.88
Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia (2009) 1.88
Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol (2011) 1.86
What should you know about limbic encephalitis? Arq Neuropsiquiatr (2012) 1.80
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology (2011) 1.75
Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology (2000) 1.75
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler (2012) 1.73
GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology (2011) 1.71
Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain (2014) 1.67
Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol (2010) 1.66
Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J (2008) 1.61
Stiff man syndrome and related conditions. Mov Disord (2002) 1.60
Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 1.59
A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58
N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord (2013) 1.55
Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler (2012) 1.54
The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology (2010) 1.44
Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord (2013) 1.43
The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr (2012) 1.43
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry (2012) 1.42
Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res (2006) 1.39
Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (2010) 1.38
Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol (2010) 1.37
Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol (2012) 1.34
Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord (2010) 1.34
Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology (2000) 1.28
GABAB receptor autoantibody frequency in service serologic evaluation. Neurology (2013) 1.28
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol (2014) 1.27
Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology (2014) 1.26
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol (2011) 6.77
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67
Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain (2013) 3.22
Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol (2012) 3.12
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain (2008) 2.91
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain (2002) 2.77
Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol (2010) 2.54
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry (2013) 2.33
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med (2007) 2.28
Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol (2009) 2.25
Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain (2006) 2.25
Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med (2010) 2.24
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry (2012) 2.15
N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol (2009) 2.03
Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol (2003) 2.02
Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol (2010) 1.99
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet (2013) 1.91
Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain (2011) 1.89
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol (2004) 1.89
Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science (2006) 1.88
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol (2012) 1.80
Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol (2003) 1.69
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol (2012) 1.67
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain (2012) 1.65
Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology (2012) 1.65
Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J (2008) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology (2004) 1.56
N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord (2013) 1.55
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clin Neurophysiol (2006) 1.54
Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol (2014) 1.50
Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disord (2005) 1.47
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature (2007) 1.46
Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry (2012) 1.45
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
A candidate gene for autoimmune myasthenia gravis. Neurology (2012) 1.44
The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr (2012) 1.43
Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol (2013) 1.40
Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res (2006) 1.39
Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (2010) 1.38
Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol (2006) 1.37
Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol (2008) 1.32
Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci (2003) 1.32
Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev Med Child Neurol (2011) 1.32
Ion channels in genetic and acquired forms of epilepsy. J Physiol (2012) 1.24
Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia (2013) 1.22
Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol (2011) 1.21
NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol (2012) 1.21
Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Dev Med Child Neurol (2011) 1.20
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol (2005) 1.20
Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol (2005) 1.19
MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain (2006) 1.18
Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry (2012) 1.16
Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve (2004) 1.15
Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol (2005) 1.14
Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia (2013) 1.13
T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. J Neuroimmunol (2011) 1.12
Autoimmune encephalitis -- new awareness, challenging questions. Discov Med (2011) 1.11
Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES. Neuropediatrics (2012) 1.11
Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology (2012) 1.11
The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol (2010) 1.10
Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia (2010) 1.10
Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry (2006) 1.10
Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol (2010) 1.09
Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol (2010) 1.08
Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry (2013) 1.07
Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord (2006) 1.07
Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. J Neurol Neurosurg Psychiatry (2007) 1.06
Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Brain (2006) 1.05
Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol (2007) 1.05
Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol (2013) 1.05
Non-paraneoplastic limbic encephalitis characterized by mesio-temporal seizures and extratemporal lesions: a case report. Seizure (2010) 1.02
Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. J Neurol Sci (2011) 1.02
New autoantibody mediated disorders of the central nervous system. Curr Opin Neurol (2003) 1.02
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun (2014) 1.01
Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease. J Neuroimmunol (2011) 1.01
MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One (2013) 1.00
Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain (2005) 0.99
Immunization against GAD induces antibody binding to GAD-independent antigens and brainstem GABAergic neuronal loss. PLoS One (2013) 0.99
Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. J Neurol (2012) 0.99
Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia (2014) 0.98
Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Gastroenterol (2007) 0.97
Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood (2007) 0.97
NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep (2011) 0.96
Diseases of the neuromuscular junction. Curr Opin Pharmacol (2002) 0.96
Ophthalmoplegic "migraine" or recurrent ophthalmoplegic cranial neuropathy: new cases and a systematic review. J Child Neurol (2012) 0.96
Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol (2007) 0.96
Anti-N-methyl-D-aspartate-receptor encephalitis in a four-year-old girl. J Pediatr (2010) 0.96